Gubra A/S
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metab… Read more
Gubra A/S (GUBRA) - Total Liabilities
Latest total liabilities as of June 2025: Dkr1.69 Billion DKK
Based on the latest financial reports, Gubra A/S (GUBRA) has total liabilities worth Dkr1.69 Billion DKK as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gubra A/S - Total Liabilities Trend (2019–2024)
This chart illustrates how Gubra A/S's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Gubra A/S Competitors by Total Liabilities
The table below lists competitors of Gubra A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Weltrend Semiconductor Inc
TW:2436
|
Taiwan | NT$2.13 Billion |
|
EUREKA FORBES LTD
NSE:EUREKAFORB
|
India | ₹22.66 Billion |
|
Lotte Chilsung Beverage
KO:005300
|
Korea | ₩2.81 Trillion |
|
NovaBridge Biosciences
NASDAQ:NBP
|
USA | $131.67 Million |
|
Beijing Quanshi World Online Net
SHE:002995
|
China | CN¥288.36 Million |
|
Jiangsu Allfavor Intelligent Circuits Technology CO.Ltd
SHE:300964
|
China | CN¥484.88 Million |
|
Poly Property Group Co. Limited
PINK:PHKIF
|
USA | $146.92 Billion |
|
Virgin Australia Holdings Ltd
AU:VGN
|
Australia | AU$5.69 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Gubra A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gubra A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gubra A/S (2019–2024)
The table below shows the annual total liabilities of Gubra A/S from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Dkr161.91 Million | +11.19% |
| 2023-12-31 | Dkr145.62 Million | -5.87% |
| 2022-12-31 | Dkr154.69 Million | +2.68% |
| 2021-12-31 | Dkr150.66 Million | +30.82% |
| 2020-12-31 | Dkr115.17 Million | +8.28% |
| 2019-12-31 | Dkr106.36 Million | -- |